The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2022

Filed:

Jun. 02, 2017
Applicants:

Ontario Institute for Cancer Research (Oicr), Toronto, CA;

University Health Network, Toronto, CA;

Inventors:

Julia A. Hopkins, Toronto, CA;

Paul Boutros, Toronto, CA;

Robert G. Bristow, Toronto, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); G16H 50/30 (2018.01); G16H 50/20 (2018.01); C12Q 1/6881 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12Q 1/6881 (2013.01); G01N 33/57434 (2013.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01);
Abstract

There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of the patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.


Find Patent Forward Citations

Loading…